文献速递血脂与心血管预防高血压

美国心血管-肾脏-代谢综合征成人心血管代谢风险因素治疗现状

Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2026-06-17

该研究基于2015年至2023年8月美国国家健康与营养调查数据,分析6384名CKM 2期及以上成人的高血压、糖尿病和血脂异常治疗率及达标率。结果显示高血压和血脂异常治疗率仅约一半,糖尿病治疗率较高,但已治疗者中血压和血糖达标率不足一半,年轻成人、女性和西班牙裔治疗率最低。

要点

  • CKM 2期及以上成人中高血压和血脂异常治疗率仅约一半。
  • 年轻成人、女性和西班牙裔治疗率显著偏低。

核心结论

  • 美国CKM综合征成人高血压和血脂异常治疗率低,已治疗者中不足一半达到血压或血糖控制目标。
  • 治疗启动不足在年轻成人、女性和西班牙裔成人中最为突出,风险因素控制不达标在高心血管风险者中尤为明显。

研究设计与样本

  • 研究分析了2015年至2023年8月美国国家健康与营养调查中6384名年龄≥20岁、CKM 2期及以上的成人。
  • 采用年龄和性别调整分析并考虑复杂抽样设计,估计治疗率和达标率。

主要发现

  • 高血压治疗率为51.3%(95%CI:49.7%-52.8%),血脂异常治疗率为48.8%(95%CI:46.7%-51.0%),糖尿病治疗率为83.4%(95%CI:80.1%-86.6%)。
  • 已治疗者中血压达标率为44.7%(95%CI:41.6%-47.7%),血糖达标率为47.3%(95%CI:42.7%-51.8%),胆固醇达标率为68.2%(95%CI:65.2%-71.1%)。
  • 20-44岁成人三种疾病治疗率均最低:高血压27.6%(95%CI:24.8%-30.3%),糖尿病73.7%(95%CI:63.8%-83.7%),血脂异常19.7%(95%CI:15.2%-24.3%)。
  • 女性和西班牙裔成人治疗率较低,高血压和血脂异常治疗率随风险分层升高而增加,但已治疗者中血压和血糖达标率在高10年CVD风险者中更低。

临床怎么用

  • 对CKM综合征患者应加强高血压和血脂异常的治疗启动,尤其关注年轻成人、女性和西班牙裔人群。
  • 已治疗患者中需强化血压和血糖管理以达到控制目标,高心血管风险者尤需注意。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome highlights the inter-related nature of cardiometabolic risk factors, kidney disease, and cardiovascular disease (CVD) and represents an important target for intervention amid rising cardiovascular mortality in the United States. However, contemporary treatment patterns of major cardiometabolic risk factors in this high-risk population are not well defined. OBJECTIVES: The purpose of this study was to characterize national treatment rates of hypertension, diabetes, and hyperlipidemia among U.S. adults with CKM syndrome and to assess risk factor control among treated individuals from 2015 through 2023. METHODS: We analyzed data from adults aged ≥20 years with CKM stage 2 and above who participated in the National Health and Nutrition Examination Survey from 2015 through August 2023. Treatment rates for hypertension, diabetes, and hyperlipidemia and rates of blood pressure, glycemic, and cholesterol control among treated individuals were estimated using age- and sex-adjusted analyses that accounted for the complex survey design. RESULTS: The study included 6,384 adults with CKM stage 2 and above (weighted mean age 44.2 years; 51.2% women). Only approximately one-half of adults with hypertension (51.3% [95% CI: 49.7%-52.8%]) or hyperlipidemia (48.8% [95% CI: 46.7%-51.0%]) were receiving treatment, while diabetes treatment rates were higher (83.4% [95% CI: 80.1%-86.6%]). Among treated individuals, blood pressure control was achieved in 44.7% (95% CI: 41.6%-47.7%), glycemic control in 47.3% (95% CI: 42.7%-51.8%), and cholesterol control in 68.2% (95% CI: 65.2%-71.1%). Treatment rates for hypertension and hyperlipidemia increased across higher risk strata, while blood pressure and glycemic control were lower among treated adults with higher 10-year CVD risk. Adults aged 20-44 years consistently had the lowest treatment rates across all 3 conditions (hypertension 27.6% [95% CI: 24.8%-30.3%], diabetes 73.7% [95% CI: 63.8%-83.7%], hyperlipidemia 19.7% [95% CI: 15.2%-24.3%]), while women were less likely than men to receive treatment for diabetes and hyperlipidemia. Among racial and ethnic subgroups, Hispanic adults had the lowest treatment rates for hypertension and hyperlipidemia. CONCLUSIONS: Among U.S. adults with CKM syndrome, treatment of hypertension and hyperlipidemia was low, and fewer than one-half of treated individuals achieved blood pressure or glycemic control. Gaps in treatment initiation were most pronounced among young adults, women, and Hispanic adults, and inadequate risk factor control was particularly evident among those with higher cardiovascular risk. These findings highlight substantial opportunities to improve cardiometabolic care in this high-risk population.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gong J, Chiu N, Clinch KA, et al. Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome. J Am Coll Cardiol. 2026. PMID: 42307495. doi:10.1016/j.jacc.2026.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。